Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?

22 Sept 2023

Abstract excerpt

As immune checkpoint inhibitors (ICI) emerge as a paradigm-shifting treatment option for patients with advanced or metastatic cancer, there is a growing demand for biomarkers that can distinguish which patients are likely to benefit. In the case of triple-negative breast cancer (TNBC), characterized by a lack of therapeutic targets, pembrolizumab approval for high-risk early-stage disease occurred regardless of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related molecular mechanisms research
Share to Mycobacterium research and diagnosis
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37835376
DOI: 10.3390/cancers15194682

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?PMID 37835376Read ↗

Multifaceted roles of long non-coding RNAs in triple-negative breast cancer: biology and clinical applications.Semantic proximity Read ↗

A Novel Immune-Related LncRNA Pair Model to Predict the Prognosis of Triple-Negative Breast CancerSemantic proximity Read ↗

Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome DataSemantic proximity Read ↗

Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancerSemantic proximity Read ↗

Identification of Robust Immune‐Associated lncRNAs Signature for Immune Checkpoint Blockade and Prognosis in Breast CancerSemantic proximity Read ↗

Identification of Prognostic Immune-Related lncRNAs Pairs in Immune Infiltration of Breast CancerSemantic proximity Read ↗

A three-long noncoding RNA signature as a diagnostic biomarker for differentiating between triple-negative and non-triple-negative breast cancersSemantic proximity Read ↗

Molecular Classification of Breast Cancer Utilizing Long Non-Coding RNA (lncRNA) Transcriptomes Identifies Novel Diagnostic lncRNA Panel for Triple-Negative Breast CancerSemantic proximity Read ↗

Expression of long non‐coding RNA ENSG 00000226738 (Lnc KLHDC 7B) is enriched in the immunomodulatory triple‐negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell deathSemantic proximity Read ↗

Let-7a/cMyc/CCAT-1/miR-17-5p Circuit Modulates PDL-1 Expression and Atezolizumab Resistance in Triple Negative Breast CancerSemantic proximity Read ↗

XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer PatientsSemantic proximity Read ↗

Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohortSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.